ENG and neoplasm: Use of CD105 antibodies to deplete CD105-positive immune cells, including macrophages, from the tumor microenvironment in addition to dinutuximab and activated NK cells decreased tumor growth and improved survival in murine models of neuroblastoma as well as a patient xenograft model compared to other combinations of therapy (182).